Long-term outcomes of progestin plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer patients

다국어 초록 (Multilingual Abstract)

Objective: The present study investigated long-term outcomes of medroxyprogesteroneacetate (MPA) plus metformin therapy in terms of control of atypical endometrial hyperplasia(AEH) and endometrial cancer (EC), and post-treatment conception.
Methods: We retrospectively analyzed 63 patients (42 with EC; 21 with AEH) who underwentfertility-sparing management using MPA plus metformin. MPA (400 mg/day) and metformin(750–2,250 mg/day) were administered to achieve complete response (CR). Metformin wasadministered until conception, even after MPA discontinuation.
Results: Of the total patients, 48 (76%) had a body mass index (BMI) ≥25 kg/m2 and 43 (68%)showed insulin resistance. Sixty-one patients (97%) achieved CR within 18 months. CR ratesat 6, 8–9, and 12 months were 60%, 84%, and 90%, respectively. During a median followupperiod of 57 months (range, 13–115 months), relapse occurred in 8 of 61 patients (13.1%)who had achieved CR. Relapse-free survival (RFS) in all patients at 5 years was 84.8%. Uponunivariate analysis, patients with BMI ≥25 kg/m2 had significantly better prognoses than didthose with BMI <25 kg/m2 (odds ratio=0.19; 95% confidence interval=0.05–0.66; p=0.009).
Overall pregnancy and live birth rates per patient were 61% (19/31) and 45% (14/31), respectively.
Conclusions: MPA plus metformin is efficacious in terms of RFS and post treatmentconception. Moreover, metformin may be more efficacious for patients with BMI ≥25 kg/m2.

참고문헌 (Reference)

1 Bonny AE, "Weight gain in obese and nonobese adolescent girls initiating depot medroxyprogesterone, oral contraceptive pills, or no hormonal contraceptive method" 160 : 40-45, 2006

2 National Comprehensive Cancer Network, "Uterine neoplasms"

3 Quinn BJ, "Repositioning metformin for cancer prevention and treatment" 24 : 469-480, 2013

4 Gallos ID, "Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia : a systematic review and metaanalysis" 207 : 266.e1-266.e12, 2012

5 Mitsuhashi A, "Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer" 27 : 262-266, 2016

6 Mangan SA, "Overweight teens at increased risk for weight gain while using depot medroxyprogesterone acetate" 15 : 79-82, 2002

7 Gunderson CC, "Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma : a systematic review" 125 : 477-482, 2012

8 Lee CH, "Obesity, adipokines and cancer: an update" 83 : 147-156, 2015

9 Pernicova I, "Metformin--mode of action and clinical implications for diabetes and cancer" 10 : 143-156, 2014

10 Tebbe C, "Metformin limits the adipocyte tumor-promoting effect on ovarian cancer" 5 : 4746-4764, 2014

11 Ko EM, "Metformin is associated with improved survival in endometrial cancer" 132 : 438-442, 2014

12 Klein J, "Metformin inhibits leptin secretion via a mitogen-activated protein kinase signalling pathway in brown adipocytes" 183 : 299-307, 2004

13 Dowling RJ, "Metformin in cancer : translational challenges" 48 : R31-43, 2012

14 Nestler JE, "Metformin for the treatment of the polycystic ovary syndrome" 358 : 47-54, 2008

15 Evans JM, "Metformin and reduced risk of cancer in diabetic patients" 330 : 1304-1305, 2005

16 Decensi A, "Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis" 3 : 1451-1461, 2010

17 Park JY, "Long-term oncologic outcomes after fertility-sparing management using oral progestin for young women with endometrial cancer (KGOG 2002)." 49 : 868-874, 2013

18 Bingyi Yang, "Insulin resistance and overweight prolonged fertility-sparing treatment duration in endometrial atypical hyperplasia patients" 대한부인종양학회 29 (29): 1-12, 2018

19 Gonthier C, "Impact of obesity on the results of fertility-sparing management for atypical hyperplasia and grade 1 endometrial cancer" 133 : 33-37, 2014

20 Francesca Falcone, "Fertility preserving treatment with hysteroscopic resection followed by progestin therapy in young women with early endometrial cancer" 대한부인종양학회 28 (28): 1-12, 2017

21 Catalano S, "Evidence that leptin through STAT and CREB signaling enhances cyclin D1 expression and promotes human endometrial cancer proliferation" 218 : 490-500, 2009

22 Rodolakis A, "European Society of Gynecological Oncology task force for fertility preservation : clinical recommendations for fertility-sparing management in young endometrial cancer patients" 25 : 1258-1265, 2015

23 Fuentes-Mattei E, "Effects of obesity on transcriptomic changes and cancer hallmarks in estrogen receptor-positive breast cancer" 106 : dju158-, 2014

24 Nestler JE, "Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome" 338 : 1876-1880, 1998

25 Mitsuhashi A, "Effects of metformin on endometrial cancer cell growth in vivo : a preoperative prospective trial" 120 : 2986-2995, 2014

26 Chu D, "Effect of metformin use on the risk and prognosis of endometrial cancer : a systematic review and meta-analysis" 18 : 438-, 2018

27 Algire C, "Diet and tumor LKB1 expression interact to determine sensitivity to anti-neoplastic effects of metformin in vivo" 30 : 1174-1182, 2011

28 Zhang Q, "Comparison among fertility-sparing therapies for well differentiated early-stage endometrial carcinoma and complex atypical hyperplasia" 8 : 57642-57653, 2017